ReviewFood chemistry: X2026
Avenanthramides as digestion-stage modulators: Mechanistic links across the gastrointestinal continuum.
Review in Food chemistry: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oat avenanthramides (AVNs) are phenolic alkaloids unique to oats and are widely recognised for their antioxidant and anti-inflammatory properties. However, human studies consistently report very low oral bioavailability (<2%), highlighting a disconnect between dietary intake and systemic exposure. This review presents a digestion-stage-resolved conceptual framework integrating current evidence on AVN fate during gastrointestinal digestion, including matrix entrapment, digestive release, limited absorption, microbial biotransformation, and interindividual metabotype variability. AVN bioaccessibility is influenced by food matrix composition, processing conditions, and enzymatic activity. Evidence indicates that AVNs may modulate starch hydrolysis, glucose transport, and resistant starch formation while undergoing chemical and Phase I transformations. In the colon, microbial metabolism produces dihydroavenanthramides (DH-AVNs), which may contribute to biological activity in a metabotype-dependent manner. Overall, AVNs appear to exert physiological effects primarily through local gastrointestinal mechanisms, although proposed pathways require confirmation in well-designed human intervention studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.